Learn More
B7-H4 Monoclonal Antibody (Clone 9), PE, eBioscience™, Invitrogen™
Rat Monoclonal Antibody
Brand: Invitrogen 12-5970-82
Description
Description: The Clone 9 monoclonal antibody reacts with mouse B7S1, also known as B7H4. B7S1 is a newly discovered member of the B7 family. It is speculated that the costimulatory regulation of T cells by B7S1 is influenced by the activation status of B cells. The ligand for B7S1 has not been identified yet. This antibody is not blocking. Simultaneous double staining of cells with two anti-mouse B7-H4 antibodies, Clone 9 and 188, suggests that epitopes recognized by these mAbs are different and/or there is no steric hindrance when antibodies are used together. Applications Reported: The Clone 9 antibody has been reported for use in flow cytometric analysis. Applications Tested: The Clone 9 antibody has been tested by flow cytometric analysis of transfected cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered.
B7-H4 (B7x, VTCN1) a costimulatory protein which is reported to function as a negative regulator of T-cell mediated immunity. Although B7-H4 binds an unknown receptor, it is thought to deliver an inhibitory signal to T-cells preventing their proliferation, cell cycle progression and interleukin-2 production. B7-H4 deficient mice are only minimally affected; suggesting B7-H4 is important in the fine tuning of the T-cell mediated immune response. B7-H4 is expressed on activated T-cells, B-cells, monocytes and dendritic cells. Aberrant expression has been associated with cancers of the lung, breast and ovary in humans. B7-H4 is expressed primarily on the membrane of lymphoid cells, and as an immunoinhibitory protein that interacts with receptors on the surface of T lymphocytes, it is involved in mediating cellular and humoral immune responses. Overexpression of B7-H4 is associated with certain malignancies, including ovarian and breast cancer, which may be a mechanism by which tumor cells suppress T cell immunity and facilitate tumor progression. Further, VTCN1 may be a useful biomarker for the early detection of ovarian cancer and Renal Cell Carcinoma (RCC).Specifications
B7-H4 | |
Monoclonal | |
0.2 mg/mL | |
PBS with 0.09% sodium azide; pH 7.2 | |
Q7TSP5 | |
Vtcn1 | |
Affinity chromatography | |
RUO | |
242122 | |
4° C, store in dark, DO NOT FREEZE! | |
Liquid |
Flow Cytometry | |
Clone 9 | |
PE | |
Vtcn1 | |
B7 family member, H4; B7 homolog 4; B7 superfamily member 1; B7h.5; B7H4; B7-H4; B7s1; B7x; BC032925; EMBL:AAH95842.1}; FLJ22418; immune costimulatory protein B7-H4; PRO1291; Protein B7S1; RGD1311204; RP11-229A19.4; t cell costimulatory molecule B7x; T-cell costimulatory molecule B7x; UNQ659/PRO1291; VCTN1; V-set domain containing T cell activation inhibitor 1; V-set domain containing T-cell activation inhibitor 1; V-set domain-containing T-cell activation inhibitor 1; Vtcn1; vtcn1 {ECO:0000312 | |
Rat | |
100 μg | |
Primary | |
Mouse | |
Antibody | |
IgG1 |
For Research Use Only.